Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

By WebmasterApril 29, 2022November 1st, 2024No Comments

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

Previous PostAnnovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
Next PostAnnovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging